Editor`s Picks

Listen up, all you Bitcoin bulls who think this current rally is a return to happier days for cryptocurrencies. We're sorry to disappoint, but we anticipate the number-one digital token by market cap...

Pre-commercial biotech group Novavax’s stock is down more than 45% in January. The FDA has not yet authorized Novavax’s vaccine for use in the US. Long-term investors could consider buying...

Value stocks have been some of this year’s best performers as investors search for companies that benefit from the improving economic outlook at the expense of high-growth technology...

Volatility is back on Wall Street, just as many analysts predicted. The widely-followed VIX index is hovering around the 29 level, its highest in a year. Meanwhile, broader indices including the Dow...

For a fourth time in five months, cotton prices have hit decade highs. For investors, the question is simple: Will the market retreat meaningfully to allow an entry off its highs, and how much higher...

Reports Q4 2021 results on Wednesday, Jan. 26, after the market close Revenue Expectation: $16.88 billion EPS Expectation: $2.25 This quarter, electric vehicle maker Tesla's (NASDAQ:TSLA) earnings...

For shareholders of Hexo (NASDAQ:HEXO) (TSX:HEXO), the past 12 months have been an up-and-down experience. And it could get even rockier as a deadline to reach a thus-far elusive milestone looms large...

Homebuilding heavyweight PulteGroup’s stock is down over 5% in January. Expected interest rate hikes and continued supply chain issues have put pressure on PHM stock as well as its...